Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 8, 2025Open Access

Identification of Therapeutic Gene Targets in Triple-Negative Breast Cancer: A Hybrid Approach Integrating Semidefinite Programming, Boolean Simulation, and Druggability Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSérgio Assunção MonteiroLCLiliana CarvalhoFSFabrício Alves Barbosa da Silva

Discussion

Loading...

Member takes

Overview

Hybrid approach combines semidefinite programming and topological network analysis to uncover therapeutic targets in triple-negative breast cancer, highlighting druggability and treatment potential.

Key Points

  • Identification of therapeutic gene targets improves druggability in triple-negative breast cancer.
  • Utilizing semidefinite programming, the study assesses critical nodes in gene regulatory networks.
  • Analysis demonstrates significant advancements in targeting strategies for triple-negative breast cancer therapies.
  • Proposed methodology ensures systematic prioritization of combination therapies based on clinical applicability.

Cite This Study

Monteiro et al. (2025) studied this question.

synapsesocial.com/papers/690e8b75a5b062d7a4e73920https://doi.org/10.1101/2025.11.05.686831
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unraveling the Complexities in TNBC Gene Interaction Networks Towards Better Therapeutics.2025 · 2 citations
  2. 2Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation2025 · 5 citations
  3. 3Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies2025 · 5 citations
  4. 4CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer2025 · 1 citations
  5. 5Research progress of molecular typing and targeted therapy for triple-negative breast cancer2025